Skip to main content

Table 4 Plasma cytokine receptor and VCAM-1 concentrations (Mean [SEM])

From: Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations

 

Baseline period

Treatment period

p*

sTNF-R I (ng/ml)

1.4 [0.05]

1.4 [0.09]

n.s.

sTNF-R II (ng/ml)

3.3 [0.3]

3.4 [0.2]

n.s.

IL-1 ra (pg/ml)

262.9 [43.2]

246.4 [37.8]

n.s.

sVCAM-1 (ng/ml)

430.7 [28.9]

484.6 [52.6]

n.s.

  1. * p for comparisons of baseline vs. treatment periods, MANOVA
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us